Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

465
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
465
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

423
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
423
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.2K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.2K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

741
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
741
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

795
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
795
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

83
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
83

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing <i>Corynebacterium glutamicum</i> as a surrogate of <i>Mycobacterium tuberculosis</i> for DNA gyrase inhibitor design.

bioRxiv : the preprint server for biology·2026
Same author

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.

Pathogens & immunity·2026
Same author

TBSure: an ESGMYC survey of pediatric TB management practices in high-income countries.

Frontiers in public health·2026
Same author

endTB-Q trial: a caveat on confounding by baseline drug resistance - Authors' reply.

The Lancet. Respiratory medicine·2026
Same author

Direct carbapenemase typing from disc diffusion antibiograms with MALCA (MAchine Learning CArbapenemase).

Nature communications·2026
Same author

Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis.

Nature communications·2026

Related Experiment Video

Updated: Dec 21, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K

Fully weekly antituberculosis regimen: a proof-of-concept study.

Fatma Kort1, Laure Fournier Le Ray1, Aurélie Chauffour1

  • 1Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France.

The European Respiratory Journal
|May 21, 2020
PubMed
Summary

Once-weekly tuberculosis treatment regimens using bedaquiline and rifapentine show superior sterilizing activity compared to daily treatments. These intermittent regimens simplify administration and may shorten tuberculosis treatment duration.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K

Related Experiment Videos

Last Updated: Dec 21, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K

Area of Science:

  • Tuberculosis research
  • Pharmacology
  • Infectious disease modeling

Background:

  • World Health Organization (WHO) guidelines recommend supervised tuberculosis treatment.
  • Intermittent drug regimens offer potential for simplified supervision and improved patient compliance.
  • Long half-life drugs like bedaquiline and rifapentine are candidates for novel intermittent tuberculosis therapies.

Purpose of the Study:

  • To evaluate the sterilizing activity of once-weekly regimens containing bedaquiline and rifapentine.
  • To compare the efficacy of novel intermittent regimens against a standard daily tuberculosis treatment in a murine model.

Main Methods:

  • A murine model of tuberculosis was established using *Mycobacterium tuberculosis* H37Rv.
  • Mice received once-weekly treatment with bedaquiline, rifapentine, and pyrazinamide (BPZ), with or without moxifloxacin and clofazimine, for 4 or 6 months.
  • Bactericidal and sterilizing activities were assessed by lung bacterial counts and relapse rates post-treatment.

Main Results:

  • Once-weekly regimens achieved negative lung cultures after 2 months, outperforming the standard daily regimen.
  • Relapse rates were significantly lower in mice treated with once-weekly regimens (0-5%) compared to the standard daily regimen (13-64%) after treatment completion.
  • BPZ-based regimens demonstrated potent sterilizing activity in the murine model.

Conclusions:

  • Once-weekly bedaquiline and rifapentine-based regimens exhibit enhanced sterilizing activity against tuberculosis compared to standard daily treatment.
  • These intermittent regimens hold promise for simplifying tuberculosis treatment administration.
  • The findings suggest potential for shortening the overall duration of tuberculosis therapy.